Sector Expert: Charles Duncan

Piper Jaffray & Co.

Image: Charles Duncan

Dr. Charles Duncan is a managing director and senior research analyst at Piper Jaffray & Co. focusing on small- and mid-cap emerging growth biotechnology companies. Duncan brings more than 18 years of sellside experience and has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis. He is a graduate of the University of Wisconsin and holds a doctorate in neuropharmacology from the University of Colorado.



Recent Interviews

With Potential Vaccines for Cancer, Ebola and Zika, Inovio Could Have an Explosive 2016 (5/18/16)
hypodermicvial630

Recent news from Inovio Pharmaceuticals Inc., a small-cap biotech developing immunotherapeutic vaccines that target cancer and infectious diseases like news-making viruses Ebola and Zika, has prompted Piper Jaffray analyst Charles Duncan to reiterate his thesis for investment in the company.

Piper Jaffray's Charles Duncan Addresses Pot Shots (6/26/14)

Early-stage biotech is a risky investment, but some bets are safer than others. Inovio Pharmaceuticals Inc. is doing high-stakes experimental work in both preventive and therapeutic medicine, addressing HIV, cancers and pre-cancers. The company's lead clinical program is in Phase 2 and a data readout is imminent, which has made the stock both volatile and an easy target for critics. In this interview with The Life Sciences Report, Senior Biotechnology Analyst and Managing Director Charles Duncan of Piper Jaffray & Co. addresses some of the criticisms that overhang the stock.

Charles Duncan: 2014 Is for Careful Stock Pickers, Not Dart Throwers (4/24/14)

Veteran Senior Biotechnology Analyst Charles Duncan of Piper Jaffray & Co. sees platform companies as the perfect way to play a consolidating market. We've had a big run in biotech, and Duncan believes now is the time to identify, through careful diligence, companies that can advance in a more temperate market. In this interview with The Life Sciences Report, Duncan discusses five biotech and specialty pharma innovators poised to produce therapies enabled by versatile and scalable technology platforms that target multiple disease indications.

Recent Quotes

"In advance of increasingly visible clinical progress expected across the platform over the next 12 months, we reiterate our Overweight rating for INO."

— Charles Duncan, Piper Jaffray & Co. (8/8/16)
more >

"INO is ahead of progress in oncology and infectious disease."

— Charles Duncan, Piper Jaffray & Co. (7/15/16)
more >

"In advance of INO's increasingly visible clinical execution in both immunotherapy and infectious diseases, we reiterate our Overweight rating."

— Charles Duncan, Piper Jaffray & Co. (5/9/16)
more >

"INO ended 2015 with $163M, sufficient to fund progress through 2017E."

— Charles Duncan, Piper Jaffray & Co. (3/14/16)
more >

"INO reported positive mouse data for its Zika vaccine."

— Charles Duncan, Piper Jaffray & Co. (2/19/16)
more >

"INO has received external validation on SynCon's flexibility and broad potential in infectious disease."

— Charles Duncan, Piper Jaffray & Co. (1/27/16)
more >

"We reiterate our Overweight rating on INO."

— Charles Duncan, Piper Jaffray & Co. (9/21/15)
more >

"The MedImmune deal further enhances our confidence in INO's DNA immunotherapy."

— Charles Duncan, Piper Jaffray & Co. (8/10/15)
more >

more comments

"We are increasing our target price for INO and we reiterate our Overweight rating."

— Charles Duncan, Piper Jaffray & Co. (5/11/15)
more >

"INO's INO-1800 for HBV will be evaluated with and without INO-9112."

— Charles Duncan, Piper Jaffray & Co. (4/21/15)
more >

"INO's SynCon is a leading immunooncology DNA-based therapeutic vaccine platform."

— Charles Duncan, Piper Jaffray & Co. (4/9/15)
more >

"DARPA's grant provides INO with funding to advance its pipeline."

— Charles Duncan, Piper Jaffray & Co. (4/8/15)
more >

"INO's clinical programs are advancing well, in line with expectations."

— Charles Duncan, Piper Jaffray & Co. (3/16/15)
more >

"Updated data from INO's Phase 2 VGX-3100 trial for CD are positive."

— Charles Duncan, Piper Jaffray & Co. (3/5/15)
more >

"Topline data from THLD's Phase 3 are expected still in Q1/16."

— Charles Duncan, Piper Jaffray & Co. (12/4/14)
more >

"Data from the Phase 1/3 GBM trial for THLD's TH-302 look positive."

— Charles Duncan, Piper Jaffray & Co. (11/17/14)
more >

"INO should initiate multiple clinical trials before year-end."

— Charles Duncan, Piper Jaffray & Co. (11/10/14)
more >

"THLD's Q3/14E cash was $68M; this is sufficient at least into 2016."

— Charles Duncan, Piper Jaffray & Co. (11/4/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.